New Team NB Position Paper on EU AI Act

In April, Team-NB published an update (version 2) of their Position Paper “European Artificial Intelligence Act”, providing insights into the implementation of the European Artificial Intelligence Act (AI Act) concerning medical devices and in vitro diagnostic medical devices. It emphasizes the need for a coordinated approach between EU member states for the designation and oversight of Notified Bodies (NBs) for AI systems, highlighting potential challenges and solutions.

Key Points from Team NB on Implementing the EU AI Act

• Implementation Challenges
  •  The AI Act, effective from August 1, 2024, introduces a risk-based approach for AI systems, particularly those used as safety components in medical devices.
  • High-risk provisions will apply from August 2, 2027, necessitating compliance for new or significantly changed medical devices.
  • Delays in national implementations could lead to a shortage of designated Notified Bodies, impacting timely compliance.
• Designation of Notified Bodies:
  • Two routes for designation: full designation under the AI Act and extended designation under existing Union harmonization legislation.
  • Swift designation is crucial to avoid backlogs and ensure access to advanced medical technology.
• Conformity Assessment:
  • Integrated processes for assessing AI systems in medical devices are required.
  • Additional attention is needed for protecting fundamental rights, risk management, human oversight, and data logging.
• Definitions and Scope:
  • Clear definitions of terms like ‘AI system’, ‘safety component’, and ‘substantial modification’ are essential for understanding the AI Act’s scope.
  • Guidance is needed to harmonize interpretations and avoid market disruptions.
•  Fundamental Rights and Data Governance:
  •  The AI Act emphasizes protecting fundamental rights, requiring manufacturers to consider these in risk assessments.
  •  High-quality data is crucial for AI systems, with Notified Bodies needing access to datasets for conformity assessments.
• Standardization and Reporting:
  •  Delays in harmonized standards could complicate conformity assessments, requiring reliance on state-of-the-art comparisons.
  • Integration of AI Act reporting requirements with existing systems is necessary to avoid duplication and ensure comprehensive oversight.

The successful implementation of the AI Act by team NB in the medical device sector depends on addressing these challenges. Clear definitions, timely national laws, robust data security, integrated reporting systems, and harmonized standards are vital for effective conformity assessments and ensuring access to innovative medical technology.

Additional information on the position paper from Team NB on the EU AI act can be found here.

For further information, contact us.

____________________________________________

Learn How MedEnvoy Can Assist you:

• EU Authorized Representative
• EU Regulatory Importer